ArticleActa biomaterialia2013
Specific VEGF sequestering to biomaterials: influence of serum stability.
Article in Acta biomaterialia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Extracellular-Matrix-Mimetic Hydrogels by Using Nanomaterials.International journal of molecular sciences · 2025Review
- VEGF-attenuated platelet-rich plasma improves therapeutic effect on cartilage repair.Biomaterials science · 2022Article
- Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives.Pharmaceutics · 2021Review
- Polysaccharide-Based Materials Created by Physical Processes: From Preparation to Biomedical Applications.Pharmaceutics · 2021Review
- Receptor mimicking TGF-β1 binding peptide for targeting TGF-β1 signaling.Biomaterials science · 2021Article
- Synthetic alternatives to Matrigel.Nature reviews. Materials · 2020Article
- Microparticle-mediated sequestration of cell-secreted proteins to modulate chondrocytic differentiation.Acta biomaterialia · 2018Article
- Versatile synthetic alternatives to Matrigel for vascular toxicity screening and stem cell expansion.Nature biomedical engineering · 2017Article
- Differential regulation of angiogenesis using degradable VEGF-binding microspheres.Biomaterials · 2016Article
- Regulating VEGF signaling in platelet concentrates via specific VEGF sequestering.Biomaterials science · 2016Article
- Stable engineered vascular networks from human induced pluripotent stem cell-derived endothelial cells cultured in synthetic hydrogels.Acta biomaterialia · 2016Article
- Thiol-norbornene photo-click hydrogels for tissue engineering applications.Journal of applied polymer science · 2015Article
- Design of growth factor sequestering biomaterials.Chemical communications (Cambridge, England) · 2014Review
- Implantation of fibrin gel on mouse lung to study lung-specific angiogenesis.Journal of visualized experiments : JoVE · 2014Article
- Serum-dependence of affinity-mediated VEGF release from biomimetic microspheres.Biomacromolecules · 2014Article
- Context clues: the importance of stem cell-material interactions.ACS chemical biology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Vascular endothelial growth factor (VEGF) was originally discovered as a tumor-derived factor that is able to induce endothelial cell behavior associated with angiogenesis. It has been implicated during wound healing for the induction of endothelial cell proliferation, tube formation and blood vessel remodeling. However, previous investigations into the biological effect of VEGF concluded that a particular range of growth factor concentrations are required for healthy vasculature to form, motivating recent studies to regulate VEGF activity via molecular sequestering to biomaterials. Numerous VEGF sequestering strategies have been developed, and they have typically relied on extracellular matrix mimicking moieties that are not specific for VEGF and can affect many growth factors simultaneously. We describe here a strategy for efficient, specific VEGF sequestering with poly(ethylene glycol) (PEG) microspheres, using peptides designed to mimic VEGF receptor type 2 (VEGFR2). By immobilizing two distinct peptides with different serum stabilities, we examined the effect of serum on the specific interaction between peptide-containing PEG microspheres and VEGF. We addressed the hypothesis that VEGF sequestering in serum-containing solutions would be influenced by the serum stability of the VEGF-binding peptide. We further hypothesized that soluble VEGF could be sequestered in serum-containing cell culture media, resulting in decreased VEGF-dependent proliferation of human umbilical vein endothelial cells. We show that soluble VEGF concentration can be effectively regulated in serum-containing environments via specific molecular sequestering, which suggests potential clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.